KRAS and cancer: For example, the missense KRAS mutations G12D and G12V are frequent in all KRAS-driven cancers, but G12R and G12C substitutions are very prevalent only in pancreatic (~15-20%) and lung (~60%) adenocarcinomas, respectively (Cox et al, 2014).